These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11734669)

  • 1. Investigation of genotype-dependent differences in factor V activity as well as response to activated protein C by application of different methods.
    Siegert G; Kostka H; Kuhlisch E; Schwarz T; Schellong SM; Jaross W
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):683-90. PubMed ID: 11734669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
    Reuner KH; Litfin F; Patscheke H
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
    Kraus M; Zander N; Fickenscher K
    Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance.
    Liebman HA; Sutherland D; Bacon R; McGehee W
    Br J Haematol; 1996 Dec; 95(3):550-3. PubMed ID: 8943900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
    Hoagland LE; Triplett DA; Peng F; Barna L
    Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
    Aboud MR; Ma DD
    Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chromogenic assay for activated protein C resistance.
    Váradi K; Moritz B; Lang H; Bauer K; Preston E; Peake I; Rivard GE; Keil B; Schwarz HP
    Br J Haematol; 1995 Aug; 90(4):884-91. PubMed ID: 7669667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
    Gaunt TR; Lowe GD; Lawlor DA; Casas JP; Day IN
    Eur J Hum Genet; 2013 Jul; 21(7):779-83. PubMed ID: 23188048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
    Ciardella AP; Yannuzzi LA; Freund KB; DiMichele D; Nejat M; De Rosa JT; Daly JR; Sisco L
    Retina; 1998; 18(4):308-15. PubMed ID: 9730172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
    Ts'ao C; Neofotistos D; Oropeza M; Vahabinejad S; Finn WG
    Am J Hematol; 1997 Mar; 54(3):214-8. PubMed ID: 9067500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Method-dependent influence of certain polymorphisms in the factor V B-domain on the response to activated protein C.
    Siegert G; Kostka H; Gehrisch S; Schwarz T; Schellong S; Jaross W
    Blood Coagul Fibrinolysis; 2000 Sep; 11(6):519-27. PubMed ID: 10997791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma.
    Jhingan A; Zhang L; Christiansen WT; Castellino FJ
    Biochemistry; 1994 Feb; 33(7):1869-75. PubMed ID: 8110790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.